Brief: Actinium Highlights Mutation Data From The Phase 3 Sierra Trial Of Iomab-B And Novel Linker Technology To Support Solid Tumor Antibody Radiation Conjugate Development At The 2024 Society Of Nuclear Medicine & Molecular Imaging Annual Meeting
10/06/2024 13:55
June 10 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM HIGHLIGHTS MUTATION DATA FROM THE PHASE 3 SIERRA
TRIAL
OF IOMAB-B AND NOVEL LINKER TECHNOLOGY TO SUPPORT SOLID TUMOR
ANTIBODY RADIATION CONJUGATE DEVELOPMENT AT THE 2024 SOCIETY OF
NUCLEAR MEDICINE & MOLECULAR IMAGING ANNUAL MEETING
* ACTINIUM PHARMACEUTICALS INC- IOMAB-B ACHIEVED PRIMARY
ENDPOINT
OF DURABLE COMPLETE REMISSION (DCR) WITH HIGH STATISTICAL
SIGNIFICANCE (P<0.0001)
Source text for Eikon: ID:nPnkWMSga
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities